Morgan Joseph Starts SeraCare Life Sciences (SRLS) at Buy; Expansion Strategy Brings New Blood To SeraCare

Morgan Joseph initiates coverage on SeraCare Life Sciences (NASDAQ: SRLS) with a Buy.

Morgan analyst says, "Since coming on board in 2006, the current management team restructured the company and returned it to profitability, and is now striving to double revenues over the next three to five years with new products and acquisitions. The company, which caters to the global life sciences market with diagnostic controls, plasma-derived reagents, molecular biomarkers, biobanking, and contract research services, is benefiting from a new lineup of quality controls for molecular tests and an increase in demand for cellular testing in drug development. Despite some near-term hiccups, we think the company is on the right track and poised to be a consolidator in a fragmented market."

For more ratings news on SeraCare Life Sciences click here and for the rating history of SeraCare Life Sciences click here.

Shares of SeraCare Life Sciences closed at $3.49 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• BMO Capital Starts Energy Fuels (UUUU) at Outperform
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy